L. Pai-Scherf

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions

Jiang Liu, Jielin Sun, Reena Philip, 2021, Clinical Cancer Research.

Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor.

I. Pastan, M. Willingham, D. Pearson, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1

I. Pastan, R. Hassan, L. Pai-Scherf, 2004, Clinical Cancer Research.

FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

K. Goldberg, R. Pazdur, M. Theoret, 2021, The oncologist.

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

K. Goldberg, P. Keegan, Amy McKee, 2017, The oncologist.

FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers.

R. Pazdur, Geoffrey Kim, G. Blumenthal, 2016 .

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials

P. Keegan, R. Pazdur, Geoffrey Kim, 2015, Clinical Cancer Research.

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Jiang Liu, Martha Donoghue, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.

I. Pastan, M. Willingham, M. Brechbiel, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

US Food and Drug Administration regulatory updates in neuro-oncology

R. Pazdur, L. Amiri-Kordestani, M. Theoret, 2021, Journal of Neuro-Oncology.